Elevated Rates of HIV Infection Among Young Aboriginal Injection Drug Users in a Canadian Setting

Overview

Journal Harm Reduct J

Publisher Biomed Central

Specialties Pharmacology
Psychiatry

Date 2006 Mar 10

PMID 16524484

Citations 21

Authors

Cari L Miller

Steffanie A Strathdee

Patricia M Spittal

Thomas Kerr

Kathy Li

Martin T Schechter

Evan Wood

Affiliations

Soon will be listed here.

Abstract

Objectives: Recent reports have suggested that Aboriginal and American Indian people are at elevated risk of HIV infection. We undertook the present study to compare socio-demographic and risk variables between Aboriginal and non-Aboriginal young (aged 13 - 24 years) injection drug users (IDUs) and characterize the burden of HIV infection among young Aboriginal IDUs.

Methods: We compared socio-demographic and risk variables between Aboriginal and non-Aboriginal young IDUs. Data were collected through the Vancouver Injection Drug Users Study (VIDUS). Semi-annually, participants have completed an interviewer-administered questionnaire and have undergone serologic testing for HIV and Hepatitis C (HCV).

Results: To date over 1500 Vancouver IDU have been enrolled and followed, among whom 291 were aged 24 years and younger. Of the 291 young injectors, 80 (27%) were Aboriginal. In comparison to non-Aboriginal youth, Aboriginal youth were more likely to test seropositive for either HIV (20% vs 7%, p=< 0.001) or Hepatitis C virus (HCV) (66% vs 38%, p =< 0.001), be involved in sex work and live in the city's IDU epi-centre at baseline. After 48 months of follow-up, Aboriginal youth experienced significantly higher HIV seroconversion rates than non-Aboriginal youth, 27.8 per ppy (95% CI: 13.4-42.2) vs. 7.0 per ppy (95% CI: 2.3-11.8) respectively (log-rank p = 0.005) and the incidence density over the entire follow-up period was 12.6 per 100 pyrs (CI: 6.49-21.96) and 3.9 per 100 pyrs (CI: 1.8-7.3) respectively.

Interpretation: These findings demonstrate that culturally relevant, evidence based prevention programs are urgently required to prevent HIV infection among Aboriginal youth.

Citing Articles

Development of Best Practice Guidelines for Primary Care to Support Patients Who Use Substances.

Hartney E, Barnard D, Richman J J Prim Care Community Health. 2020; 11:2150132720963656.

PMID: 33176537 PMC: 7675907. DOI: 10.1177/2150132720963656.

Hepatitis C Virus Infection in Indigenous Populations in the United States and Canada.

Bruce V, Eldredge J, Leyva Y, Mera J, English K, Page K Epidemiol Rev. 2019; 41(1):158-167.

PMID: 31781749 PMC: 7305812. DOI: 10.1093/epirev/mxz015.

A qualitative study on the intersectional social determinants for indigenous people who become infected with HIV in their youth.

Woodgate R, Zurba M, Tennent P, Cochrane C, Payne M, Mignone J Int J Equity Health. 2017; 16(1):132.

PMID: 28732498 PMC: 5521109. DOI: 10.1186/s12939-017-0625-8.

Perceptions of a drug prevention public service announcement campaign among street-involved youth in Vancouver, Canada: a qualitative study.

Ti L, Fast D, Small W, Kerr T Harm Reduct J. 2017; 14(1):3.

PMID: 28086787 PMC: 5237277. DOI: 10.1186/s12954-017-0132-7.

HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence.

Fraser H, Mukandavire C, Martin N, Hickman M, Cohen M, Miller W Int J Epidemiol. 2016; 46(2):466-478.

PMID: 27524816 PMC: 5837590. DOI: 10.1093/ije/dyw180.

References

Strain E, Bigelow G, Liebson I, Stitzer M . Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999; 281(11):1000-5. DOI: 10.1001/jama.281.11.1000. View

Tyndall M, Craib K, Currie S, Li K, OShaughnessy M, Schechter M . Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr. 2001; 28(4):351-7. DOI: 10.1097/00126334-200112010-00008. View

Des Jarlais D, Minkoff H, Hoegsberg B, Landesman S, Tross S . Crack use and multiple AIDS risk behaviors. J Acquir Immune Defic Syndr (1988). 1991; 4(4):446-7. View

Spittal P, Craib K, Wood E, Laliberte N, Li K, Tyndall M . Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ. 2002; 166(7):894-9. PMC: 100922. View

Craib K, Spittal P, Wood E, Laliberte N, Hogg R, Li K . Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ. 2003; 168(1):19-24. PMC: 139313. View

Simoni J, Sehgal S, Walters K . Triangle of risk: urban American Indian women's sexual trauma, injection drug use, and HIV sexual risk behaviors. AIDS Behav. 2004; 8(1):33-45. DOI: 10.1023/b:aibe.0000017524.40093.6b. View

Strathdee S, Patrick D, Currie S, Cornelisse P, Rekart M, Montaner J . Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997; 11(8):F59-65. DOI: 10.1097/00002030-199708000-00001. View

Spittal P, Schechter M . Injection drug use and despair through the lens of gender. CMAJ. 2001; 164(6):802-3. PMC: 80877. View

Chiasson M, Stoneburner R, Hildebrandt D, Ewing W, Telzak E, Jaffe H . Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack). AIDS. 1991; 5(9):1121-6. DOI: 10.1097/00002030-199109000-00011. View

10.

Edlin B, Irwin K, Faruque S, McCoy C, Word C, Serrano Y . Intersecting epidemics--crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N Engl J Med. 1994; 331(21):1422-7. DOI: 10.1056/NEJM199411243312106. View

11.

Strathdee S, Galai N, Safaiean M, Celentano D, Vlahov D, Johnson L . Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. Arch Intern Med. 2001; 161(10):1281-8. DOI: 10.1001/archinte.161.10.1281. View

12.

Vernon I, Jumper-Thurman P . Prevention of HIV/AIDS in Native American communities: promising interventions. Public Health Rep. 2002; 117 Suppl 1:S96-103. PMC: 1913700. View

13.

Strathdee S, Patrick D, Archibald C, Ofner M, Cornelisse P, Rekart M . Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada. Addiction. 1998; 92(10):1339-47. View

14.

Schutz C, Rapiti E, Vlahov D, Anthony J . Suspected determinants of enrollment into detoxification and methadone maintenance treatment among injecting drug users. Drug Alcohol Depend. 1994; 36(2):129-38. DOI: 10.1016/0376-8716(94)90095-7. View

15.

Saxon A, Wells E, Fleming C, Jackson T, Calsyn D . Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction. 1996; 91(8):1197-209. DOI: 10.1046/j.1360-0443.1996.918119711.x. View

16.

Thomas S, Quinn S . The Tuskegee Syphilis Study, 1932 to 1972: implications for HIV education and AIDS risk education programs in the black community. Am J Public Health. 1991; 81(11):1498-505. PMC: 1405662. DOI: 10.2105/ajph.81.11.1498. View

17.

Wood E, Spittal P, Kerr T, Small W, Tyndall M, OShaughnessy M . Requiring help injecting as a risk factor for HIV infection in the Vancouver epidemic: implications for HIV prevention. Can J Public Health. 2003; 94(5):355-9. PMC: 6979944. View

18.

Wood E, Tyndall M, Spittal P, Li K, Hogg R, Montaner J . Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS. 2002; 16(6):941-3. DOI: 10.1097/00002030-200204120-00021. View

19.

Shah N, Celentano D, Vlahov D, Stambolis V, Johnson L, Nelson K . Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. AIDS. 2000; 14(13):2035-43. DOI: 10.1097/00002030-200009080-00020. View

20.

Tyndall M, Currie S, Spittal P, Li K, Wood E, OShaughnessy M . Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003; 17(6):887-93. DOI: 10.1097/00002030-200304110-00014. View